Every year in the U.S., colorectal cancer (CRC) affects more than 136,830 people and is the third most commonly diagnosed cancer in both men and women. However, it’s also one of the most preventable and, if found early, most treatable forms of cancer. Through prevention and early detection, screening can significantly reduce both the incidence and mortality rates of CRC, lower lifetime treatment costs and save lives.

In a Q&A with Gastroenterology & Endoscopy News, BioIQ’s Chief Medical Officer Josh Sclar, MD, MPH, discusses what gastroenterologists really need to know about effective CRC screening programs and weighs in on whether screening guidelines need to be revisited, following reports that millennials face an increased risk of the disease.

Read the complete Q&A to learn more.

 

Share This